What is tesamorelin?
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH), given by subcutaneous injection and best known as Egrifta. It is FDA-approved for reducing excess visceral fat, the deep abdominal fat around the organs, in adults living with HIV who have lipodystrophy.
What makes it interesting well beyond that niche is the design. Instead of supplying growth hormone directly, tesamorelin works upstream, prompting the body's own pituitary to release growth hormone in its natural pulsatile rhythm. An approved, upstream, rhythm-preserving approach to growth-hormone signaling is exactly what draws attention from anyone thinking about body composition and metabolic health.
How does it work?
Tesamorelin binds the GHRH receptors in the pituitary gland, and the pituitary answers the way it was built to: releasing growth hormone in pulses, the pattern the body uses naturally. The downstream effects on fat tissue follow from that restored signaling, and the FDA prescribing information describes the same binding-and-release mechanism.
The pulsatility matters. Injected growth hormone imposes a constant elevated level; a GHRH analog asks the body's own control system to do the work, preserving its feedback loops. That is why the trials focused on visceral and liver fat, the metabolically active depots growth-hormone signaling governs most directly, and why blood sugar and IGF-1 are monitored along the way.
Why it matters in regenerative medicine
Visceral and liver fat are not cosmetic problems; they are the metabolically dangerous depots tied to inflammation, insulin resistance, and cardiovascular risk, and they respond poorly to diet alone in many people. A medication with randomized-trial evidence of shrinking exactly those depots, through the body's own signaling, sits naturally in metabolic and longevity conversations. The honest asterisk, carried through this whole article, is that its trial record was built in HIV populations, and extrapolating beyond them is exactly that: extrapolation.
What the trials showed
The approval rests on a large phase 3 program whose pivotal trial randomized 412 adults with HIV and excess abdominal fat to tesamorelin 2mg daily or placebo, with visceral adipose tissue as the primary measure. A 2014 randomized trial in JAMA then quantified the depot effects directly: a net visceral-fat reduction of about 42 cm2 versus placebo, along with reduced liver fat.
The liver result deepened in a 2019 randomized multicentre trial in The Lancet HIV: over 12 months, liver fat fell roughly 37% from baseline, 35% of treated participants dropped below the healthy liver-fat threshold versus 4% on placebo, and progression of liver fibrosis was limited. A 2025 phase 2 trial exploring cognition reduced waist circumference but found no clear cognitive benefit, and a recruiting phase 2 program is now testing tesamorelin with exercise for muscle and physical function in older adults with HIV.
What people notice in practice
What users report, labeled honestly as experience rather than trial evidence, centers on the midsection: waistlines shrinking over months where diet had stalled, better sleep quality early on, and gradual body-composition shifts rather than scale drama. Water retention and injection-site reactions are the commonly mentioned nuisances, and joint achiness appears in some reports, consistent with raised growth-hormone signaling.
The monitoring story belongs in practice too: because the mechanism raises growth hormone and IGF-1, responsible use means periodic blood work rather than a buy-and-forget approach.
The pros and the cons
What's promising
- FDA-approved, with a 412-person phase 3 trial behind it.
- Randomized evidence of reduced visceral fat and a 37% liver-fat reduction with less fibrosis progression.
- Works through the body's own pulsatile growth-hormone rhythm rather than overriding it.
- An active research program extending toward muscle and physical function.
What's uncertain
- The strong evidence lives in HIV-associated lipodystrophy; use beyond it is extrapolation.
- The cognition trial reduced waistlines but not the endpoint it chased.
- Effects reverse after stopping, so duration is an open question.
- Raised growth-hormone signaling requires monitoring of blood sugar and IGF-1.
Worth considering
- Daily injections and lab monitoring make this a commitment, not a casual add-on.
- Anyone with diabetes risk needs the blood-sugar conversation before starting.
- Sourcing matters: an approved pharmaceutical exists, which sets the quality bar.
- Visceral fat responds to training and nutrition too; the medication is a tool within that work.
Why the evidence looks the way it does
Tesamorelin's trials were funded to solve a specific problem, HIV-associated lipodystrophy, so that is where the randomized evidence lives. The biology it targets, visceral and liver fat through growth-hormone signaling, is not HIV-specific, which is why interest extends beyond the label. Extending the evidence costs trials someone must fund, and the current muscle-and-function study is one of the few doing it. The familiar rule, one more time: beyond the studied populations, untested is untested, in both directions.
What the key trials tested
Our framing rule for evidence: a trial tests one dose, one duration, one population, one endpoint. Where the evidence sits:
Preclinical & practice
The body-composition and longevity uses beyond the label.
Early trials
Cognition (no clear benefit); muscle and physical function with exercise, recruiting now.
Late-stage trials
The 412-person pivotal phase 3 in HIV-associated abdominal fat.
Approved uses
Excess visceral fat in HIV-associated lipodystrophy (Egrifta).
Every study behind this article is filterable in our research library on the Science page.
Questions people ask
How is this different from taking growth hormone?
Direction and rhythm. Growth hormone injections impose a constant outside supply; tesamorelin prompts your own pituitary to release growth hormone in its natural pulses, preserving the body's feedback control. That upstream design is why many clinicians consider the GHRH-analog approach the more physiological way to restore the signal.
Does it work outside of HIV lipodystrophy?
Honestly: the randomized evidence was built in HIV populations, and that is where the 42 cm2 visceral-fat and 37% liver-fat numbers come from. The mechanism is not HIV-specific, which makes extrapolation tempting and common, but tested-in-a-population and works-in-everyone are different claims, and the trials extending the evidence are only now running.
What monitoring does it need?
Blood sugar and IGF-1, because the whole point of the medication is raising growth-hormone signaling, which can push both. The trials tracked them routinely and practice should too: baseline labs, periodic rechecks, and a physician who adjusts course on the numbers rather than the mirror.
What happens when you stop?
The visceral-fat effect reverses over time after discontinuation, because the restored signal stops being restored. That makes tesamorelin a maintenance tool rather than a cure, and it puts the exit question, how long, toward what goal, with what habits underneath, into the first conversation rather than the last.
What to take away
If you remember five things from this article, make them these:
- Tesamorelin is an FDA-approved GHRH analog that restores the body's own pulsatile growth-hormone release.
- Its randomized trials show real reductions in visceral and liver fat, the metabolically dangerous depots.
- That evidence lives in HIV-associated lipodystrophy; wider use is extrapolation with a plausible mechanism.
- It requires commitment: daily injections, lab monitoring, and effects that reverse on stopping.
- Used well, it is a tool inside metabolic care, alongside training and nutrition, with a physician on the numbers.
The evidence
Selected references, each verified against primary sources (PubMed, ClinicalTrials.gov, and the FDA label). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Tesamorelin is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.